Aromasin (Exemestane) 25 mg – 30 Tablets

Biochem Aromasin (Exemestane) 25 mg – 30 Tablets | Oral Steroidal Aromatase Inhibitor

Biochem Aromasin (Exemestane) 25 mg – 30 Tablets is a product containing exemestane, an orally active steroidal aromatase inhibitor used in selected hormone receptor-positive breast cancer treatment settings.

Exemestane belongs to the class of third-generation steroidal aromatase inhibitors. Its principal pharmacological action involves irreversible inactivation of aromatase, the enzyme responsible for converting androgen precursors into estrogens.

Exemestane is commercially associated with the pharmaceutical brand name Aromasin. It has established medical applications in the treatment of certain hormone receptor-positive breast cancers in postmenopausal women.

Unlike nonsteroidal aromatase inhibitors such as anastrozole (Arimidex) and letrozole (Femara), exemestane is a steroidal, mechanism-based aromatase inactivator.

Its molecular structure resembles androstenedione, a naturally occurring steroid involved in estrogen biosynthesis. This structural similarity allows exemestane to interact with the aromatase catalytic system.

Following interaction with aromatase, exemestane produces irreversible enzyme inactivation. Restoration of aromatase activity requires synthesis of new functional enzyme molecules.

Aromatase, also known as CYP19A1, is a cytochrome P450 enzyme responsible for converting androstenedione into estrone and testosterone into estradiol.

By inactivating this enzyme, exemestane reduces estrogen biosynthesis in tissues where aromatase is expressed.

Although exemestane has a steroidal chemical structure, it is not classified as an anabolic-androgenic steroid. Its primary clinical activity is aromatase inhibition rather than androgen receptor activation.

Exemestane has also been studied in selected endocrine and reproductive conditions. However, its established indications, clinical evidence, and safety considerations vary between patient populations.

The use of aromatase inhibitors to manage hormonal changes associated with anabolic steroid exposure is not an established indication. Excessive estrogen suppression can adversely affect bone health, sexual function, lipid metabolism, and other physiological systems.

Aromasin is a pharmaceutical brand name associated with exemestane. Its use in a Biochem product description does not establish that the product is authentic branded Aromasin or therapeutically equivalent to an authorized pharmaceutical preparation.

The Biochem Exemestane product is described as containing 25 mg per tablet, with 30 tablets per package. This represents a total labeled active ingredient content of 750 mg per package.

The stated strength does not constitute an individual dosage recommendation. Product identity, purity, excipients, and manufacturing specifications have not been independently verified.

1. Irreversibly Inactivates the Aromatase Enzyme

Exemestane interacts with aromatase, the enzyme responsible for converting androgen precursors into estrogens.

Its steroidal structure allows it to act as a mechanism-based inhibitor, leading to irreversible enzyme inactivation.

Unlike reversible inhibitors, the affected enzyme cannot regain activity simply through dissociation of the inhibitor. Restoration of enzyme activity requires production of new functional aromatase.

2. Reduces Estrogen Biosynthesis

Exemestane reduces estrogen production by inhibiting the conversion of androgen precursors into estrone and estradiol.

This effect is especially relevant in postmenopausal women, whose estrogen production depends substantially on peripheral aromatization.

The magnitude of estrogen suppression depends on individual physiology, underlying medical conditions, and treatment circumstances.

3. Has Established Applications in Hormone-Sensitive Breast Cancer

Exemestane is used in selected treatment settings involving hormone receptor-positive breast cancer in postmenopausal women.

Reducing estrogen availability can decrease hormonal stimulation of estrogen-dependent cancer cells.

Clinical use requires an appropriate diagnosis, individualized treatment planning, and professional medical supervision.

4. Functions as a Steroidal Aromatase Inactivator

Exemestane is structurally related to androstenedione, a naturally occurring steroid involved in estrogen biosynthesis.

Its mechanism differs from nonsteroidal aromatase inhibitors such as anastrozole and letrozole.

Exemestane irreversibly inactivates aromatase, whereas anastrozole and letrozole inhibit aromatase reversibly.

5. Does Not Directly Block Estrogen Receptors

Exemestane does not primarily function as an estrogen receptor antagonist.

Instead, it reduces estrogen synthesis through enzyme inactivation.

This distinguishes its mechanism from selective estrogen receptor modulators such as tamoxifen, which interact directly with estrogen receptors.

6. Influences Hormonal Regulation

Estrogens contribute to bone metabolism, reproductive function, cardiovascular physiology, and other biological processes in both women and men.

Reducing estrogen concentrations may alter these functions.

In men, aromatase inhibition can influence estradiol and testosterone concentrations, but routine use without a defined medical indication is not established.

7. Has Important Bone, Musculoskeletal, and Cardiovascular Safety Considerations

Exemestane can reduce bone mineral density and increase fracture risk in susceptible individuals.

Other reported adverse effects include hot flashes, joint pain, fatigue, sweating, headache, and nausea.

Cardiovascular and metabolic risk assessment may be important depending on the patient's underlying condition and medical history.

Exemestane carries clinically important risks, including bone loss, fractures, musculoskeletal symptoms, and adverse effects associated with estrogen depletion. Serious hypersensitivity reactions and liver-related adverse effects have also been reported. It should not be used during pregnancy because fetal harm may occur. Its use in premenopausal women requires special clinical considerations and, in certain breast cancer settings, appropriate ovarian suppression.

The 25 mg tablet strength describes the labeled quantity of exemestane per tablet. It does not independently establish an appropriate dosage, administration frequency, treatment duration, or individual medical indication.

Exemestane is an orally active steroidal aromatase inhibitor whose principal mechanism involves irreversible inactivation of CYP19A1.

Its pharmacological activity differs from anabolic-androgenic steroids because its primary action is suppression of estrogen biosynthesis rather than direct androgen receptor stimulation.

Step 1 – Oral Administration and Gastrointestinal Absorption

Exemestane is administered orally in established pharmaceutical formulations.

Following administration, it is absorbed through the gastrointestinal tract and enters systemic circulation.

Food can increase systemic exposure to exemestane, making formulation and administration conditions relevant to its pharmacokinetic characteristics.

Step 2 – Distribution to Tissues Expressing Aromatase

Following absorption, exemestane distributes throughout the body and reaches tissues where aromatase is expressed.

These include adipose tissue, breast tissue, and other peripheral sites involved in estrogen production.

Step 3 – Irreversible Inactivation of Aromatase

Exemestane interacts with aromatase and causes mechanism-based inactivation of the enzyme.

This reduces the conversion of androstenedione into estrone and testosterone into estradiol.

Because enzyme inactivation is irreversible, restoration of aromatase activity depends on synthesis of new functional enzyme.

Step 4 – Reduction of Estrogen-Dependent Signaling

By reducing estrogen production, exemestane can decrease stimulation of estrogen-dependent cellular pathways.

This mechanism underlies its clinical role in selected hormone receptor-positive breast cancer treatment settings.

Excessive estrogen suppression can also negatively affect bone, joints, and other tissues.

Step 5 – Hepatic Metabolism and Elimination

Exemestane undergoes extensive hepatic metabolism involving oxidation, reduction, and conjugation reactions.

Its metabolites and associated elimination products are excreted through renal and fecal pathways.

The terminal elimination half-life of exemestane is approximately 24 hours, although its effects on aromatase activity can persist beyond the presence of the parent compound because enzyme inactivation is irreversible.

Exemestane has been manufactured in oral solid-dose pharmaceutical formulations, including 25 mg tablets.

The Biochem Aromasin 25 mg oral tablet presentation is described by the following characteristics:

• Exemestane as the labeled